169 related articles for article (PubMed ID: 34074809)
21. POTENTIAL LIFE PROGNOSTIC MARKER FOR MESENCHYMAL TUMOR RESEMBLING UTERINE LEIOMYOSARCOMA.
Nishikawa S; Hayashi T; Uzaki T; Yaegashi N; Abiko K; Konishi I
Georgian Med News; 2023 Oct; (343):119-126. PubMed ID: 38096528
[TBL] [Abstract][Full Text] [Related]
22. Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
J Soc Gynecol Investig; 2004 Apr; 11(3):187-91. PubMed ID: 15051039
[TBL] [Abstract][Full Text] [Related]
23. Practical issues in uterine pathology from banal to bewildering: the remarkable spectrum of smooth muscle neoplasia.
Oliva E
Mod Pathol; 2016 Jan; 29 Suppl 1():S104-20. PubMed ID: 26715170
[TBL] [Abstract][Full Text] [Related]
24. Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential.
O'Neill CJ; McBride HA; Connolly LE; McCluggage WG
Histopathology; 2007 Jun; 50(7):851-8. PubMed ID: 17543074
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic criteria for uterine smooth muscle tumors: leiomyoma variants associated with malignant behavior.
Giuntoli RL; Gostout BS; DiMarco CS; Metzinger DS; Keeney GL
J Reprod Med; 2007 Nov; 52(11):1001-10. PubMed ID: 18161397
[TBL] [Abstract][Full Text] [Related]
26. Immunoexpression of progesterone receptor, epithelial growth factor receptor and galectin-3 in uterine smooth muscle tumors.
Soltan MM; Albasry AM; Eldosouky MK; Abdelhamid HS
Cell Mol Biol (Noisy-le-grand); 2018 Apr; 64(5):7-12. PubMed ID: 29729689
[TBL] [Abstract][Full Text] [Related]
27. Criteria for risk stratification of vulvar and vaginal smooth muscle tumors: a follow-up study with application to leiomyoma variants, smooth muscle tumors of uncertain malignant potential, and leiomyosarcomas.
Swanson AA; Howitt BE; Schoolmeester JK
Hum Pathol; 2020 Sep; 103():83-94. PubMed ID: 32687944
[TBL] [Abstract][Full Text] [Related]
28. Fascin expression in uterine smooth muscle tumors.
Kefeli M; Yildiz L; Kaya FC; Aydin O; Kandemir B
Int J Gynecol Pathol; 2009 Jul; 28(4):328-33. PubMed ID: 19483633
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical analysis in the diagnosis of uterine myometrial smooth muscle tumors.
Stănescu AD; Nistor E; Sajin M; Stepan AE
Rom J Morphol Embryol; 2014; 55(3 Suppl):1129-36. PubMed ID: 25607395
[TBL] [Abstract][Full Text] [Related]
30. Leiomyoma With Bizarre Nuclei: Clinical and Pathologic Features of 30 Patients.
Kefeli M; Caliskan S; Kurtoglu E; Yildiz L; Kokcu A
Int J Gynecol Pathol; 2018 Jul; 37(4):379-387. PubMed ID: 28700441
[TBL] [Abstract][Full Text] [Related]
31. Differential diagnosis of uterine smooth muscle tumors using diffusion-weighted imaging: correlations with the apparent diffusion coefficient and cell density.
Tasaki A; Asatani MO; Umezu H; Kashima K; Enomoto T; Yoshimura N; Aoyama H
Abdom Imaging; 2015 Aug; 40(6):1742-52. PubMed ID: 25526683
[TBL] [Abstract][Full Text] [Related]
32. Mass lesions of the myometrium: interpretation and management of unexpected pathology.
Porter AE; Kho KA; Gwin K
Curr Opin Obstet Gynecol; 2019 Oct; 31(5):349-355. PubMed ID: 31425175
[TBL] [Abstract][Full Text] [Related]
33. EMMPRIN (CD147) Expression in Smooth Muscle Tumors of the Uterus.
Kefeli M; Yildiz L; Gun S; Ozen FZ; Karagoz F
Int J Gynecol Pathol; 2016 Jan; 35(1):1-7. PubMed ID: 26352545
[TBL] [Abstract][Full Text] [Related]
34. Epithelioid smooth muscle tumors of the uterus do not express CD1a: a potential immunohistochemical adjunct in their distinction from uterine perivascular epithelioid cell tumors.
Fadare O; Liang SX
Ann Diagn Pathol; 2008 Dec; 12(6):401-5. PubMed ID: 18995203
[TBL] [Abstract][Full Text] [Related]
35. Pathology of uterine leiomyosarcomas and smooth muscle tumours of uncertain malignant potential.
Ip PP; Cheung AN
Best Pract Res Clin Obstet Gynaecol; 2011 Dec; 25(6):691-704. PubMed ID: 21865091
[TBL] [Abstract][Full Text] [Related]
36. An immunohistochemical analysis of stathmin 1 expression in uterine smooth muscle tumors: differential expression in leiomyosarcomas and leiomyomas.
Allen MM; Douds JJ; Liang SX; Desouki MM; Parkash V; Fadare O
Int J Clin Exp Pathol; 2015; 8(3):2795-801. PubMed ID: 26045786
[TBL] [Abstract][Full Text] [Related]
37. Epithelioid Leiomyosarcoma of the Uterus: Modern Outcome-based Appraisal of Diagnostic Criteria in a Large Institutional Series.
Chapel DB; Nucci MR; Quade BJ; Parra-Herran C
Am J Surg Pathol; 2022 Apr; 46(4):464-475. PubMed ID: 34419987
[TBL] [Abstract][Full Text] [Related]
38. Unusual types of smooth muscle tumors of uterine corpus: case reports and literature review.
Makharoblidze E; Goishvili N; Mchedlishvili M; Khakhutaishvili I; Jangavadze M
Georgian Med News; 2013 Mar; (216):7-11. PubMed ID: 23567300
[TBL] [Abstract][Full Text] [Related]
39. Smooth Muscle Tumors of the Visceral Adnexal and Uterine Ligaments and Adnexal Connective Tissue: A Clinicopathologic Study of 67 Cases.
Patel V; Xing D; Feely M; Schoolmeester JK
Int J Gynecol Pathol; 2020 Jan; 39(1):55-67. PubMed ID: 30702465
[TBL] [Abstract][Full Text] [Related]
40. Analysis of allelic loss as an adjuvant tool in evaluation of malignancy in uterine smooth muscle tumors.
Esposito NN; Hunt JL; Bakker A; Jones MW
Am J Surg Pathol; 2006 Jan; 30(1):97-103. PubMed ID: 16330948
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
